GlassScriptPhysician profile
Christine Le
NPI 1447710371
$3,033.59
in general payments reported to CMS, 2019-2025
18 companies · $695 in 2025
The $695 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.84 · 2022: $928 · 2023: $620 · 2024: $747 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $982.99 | 2022-2024 | Trevo, Surpass Evolve, Evolve |
| Silk Road Medical, INC. | $703.70 | 2022-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Boston Scientific Corporation | $392.53 | 2025 | Enroute Transcarotid Neuroprotection System |
| Integra Lifesciences Corporation | $192.21 | 2022 | |
| Depuy Synthes Sales INC. | $138.51 | 2021-2023 | Teligen, Symphony |
| Medtronic, INC. | $134.45 | 2023-2025 | Catalyft Pl Expandable Interbody System, Mazor X System, Kyphon Express II Kyphopak Tray |
| Novartis Pharmaceuticals Corporation | $120.12 | 2024-2025 | |
| Ucb, INC. | $88.41 | 2024-2025 | Rystiggo, Nayzilam |
| Globus Medical, INC. | $79.03 | 2022 | |
| Heartflow, INC. | $31.75 | 2025 | |
| Janssen Pharmaceuticals, INC | $25.00 | 2021 | |
| Merz Pharmaceuticals, LLC | $24.28 | 2024 | Xeomin |
| Lilly USA, LLC | $23.29 | 2024 | Amyvid, Kisunla |
| Abbvie INC. | $21.33 | 2025 | |
| Biogen, INC. | $19.86 | 2024 | Skyclarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $19.74 | 2024 | Vyepti |
| Azurity Pharmaceuticals, INC. | $18.67 | 2025 | Horizant |
| Genentech USA, INC. | $17.72 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.